# SHR-1701 in Patients With Recurrent/Metastatic Scchn

> **NCT04650633** · PHASE2 · UNKNOWN · sponsor: **Jiangsu HengRui Medicine Co., Ltd.** · enrollment: 130 (estimated)

## Conditions studied

- Squamous Cell Carcinoma of Head and Neck

## Interventions

- **DRUG:** SHR-1701

## Key facts

- **NCT ID:** NCT04650633
- **Lead sponsor:** Jiangsu HengRui Medicine Co., Ltd.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2021-05-07
- **Primary completion:** 2023-01
- **Final completion:** 2023-01
- **Target enrollment:** 130 (ESTIMATED)
- **Last updated:** 2021-10-29


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04650633

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04650633, "SHR-1701 in Patients With Recurrent/Metastatic Scchn". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT04650633. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*